Revised SPC: Sevodyne (buprenorphine) transdermal patch

SPC now warns of risk of serotonin syndromewhen co-administered with other serotonergic agents, e.g. MAO inhibitors, SSRIs, SNRIs or tricyclic antidepressants. If co-administration is warranted, careful observation is advised, especially during initiation and dose increases.

Source:

electronic Medicines compendium